Literature DB >> 11302866

Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis.

J M Albers1, L Paimela, P Kurki, K B Eberhardt, P Emery, M A van 't Hof, F H Schreuder, M Leirisalo-Repo, P L van Riel.   

Abstract

OBJECTIVE: To compare four different inception cohorts of patients with early rheumatoid arthritis (RA) with respect to treatment strategies, disease activity, and outcome during a five year follow up period.
METHOD: Data from cohorts of patients with early RA, with a standardised assessment at least every six months for five years from four different centres, were included in one database. Owing to slight differences in the individual study designs, linearly interpolated values were calculated to complete the standard follow up schedule.
RESULTS: Despite similar inclusion criteria, significant differences in demographic factors and baseline disease activity were found between the different cohorts. During the follow up an aggressive treatment strategy was followed in the Dutch and Finnish cohort, an intermediate strategy in the British cohort, and a conservative strategy in the Swedish cohort. A significant improvement in disease activity was seen in all cohorts, though the most rapid and striking improvement was seen in those receiving aggressive treatment. This resulted in less radiographic destruction in the long run.
CONCLUSION: This observational study of cohorts of patients with early RA confirms that early aggressive treatment results not only in a more rapid reduction of disease activity but also in less radiographic progression in the long term.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302866      PMCID: PMC1753652          DOI: 10.1136/ard.60.5.453

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

1.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Authors:  D M van der Heijde; M A van 't Hof; P L van Riel; L A Theunisse; E W Lubberts; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

2.  Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films.

Authors:  A Larsen; K Dale; M Eek
Journal:  Acta Radiol Diagn (Stockh)       Date:  1977-07

3.  Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.

Authors:  M Dougados; B Combe; A Cantagrel; P Goupille; P Olive; M Schattenkirchner; S Meusser; L Paimela; R Rau; H Zeidler; M Leirisalo-Repo; K Peldan
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

4.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

5.  No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset.

Authors:  E J Kroot; M A van Leeuwen; M H van Rijswijk; M L Prevoo; M A Van 't Hof; L B van De Putte; P L van Riel
Journal:  Ann Rheum Dis       Date:  2000-12       Impact factor: 19.103

6.  Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis.

Authors:  D M van der Heijde; P L van Riel; I H Nuver-Zwart; F W Gribnau; L B vad de Putte
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

7.  Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients.

Authors:  D M van der Heijde; P L van Riel; M A van Leeuwen; M A van 't Hof; M H van Rijswijk; L B van de Putte
Journal:  Br J Rheumatol       Date:  1992-08

8.  Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants.

Authors:  M A van Leeuwen; D M van der Heijde; M H van Rijswijk; P M Houtman; P L van Riel; L B van de Putte; P C Limburg
Journal:  J Rheumatol       Date:  1994-03       Impact factor: 4.666

9.  Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study.

Authors:  P Hannonen; T Möttönen; M Hakola; M Oka
Journal:  Arthritis Rheum       Date:  1993-11

10.  Early rheumatoid arthritis: therapeutic strategies.

Authors:  P Emery
Journal:  Scand J Rheumatol Suppl       Date:  1994
View more
  13 in total

1.  Differences in activity limitation, pain intensity, and global health in patients with rheumatoid arthritis in Sweden and the USA: a 5-year follow-up.

Authors:  M Björk; L Trupin; I Thyberg; P Katz; E Yelin
Journal:  Scand J Rheumatol       Date:  2011-09-21       Impact factor: 3.641

2.  Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.

Authors:  Peter K Schädlich; Henning Zeidler; Angela Zink; Erika Gromnica-Ihle; Matthias Schneider; Christoph Straub; Josef G Brecht; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics.

Authors:  C Carli; A G C Ehlin; L Klareskog; S Lindblad; S M Montgomery
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

4.  Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology.

Authors:  X Le Loët; J M Berthelot; A Cantagrel; B Combe; M De Bandt; B Fautrel; R M Flipo; F Lioté; J F Maillefert; O Meyer; A Saraux; D Wendling; F Guillemin
Journal:  Ann Rheum Dis       Date:  2005-06-30       Impact factor: 19.103

5.  Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.

Authors:  Eiichi Tanaka; Ajitha Mannalithara; Eisuke Inoue; Noriko Iikuni; Atsuo Taniguchi; Shigeki Momohara; Gurkirpal Singh; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-12-16       Impact factor: 2.631

6.  Comparison of foot pain and foot care among rheumatoid arthritis patients taking and not taking anti-TNFα therapy: an epidemiological study.

Authors:  S J Otter; K Lucas; K Springett; A Moore; K Davies; A Young; K Walker-Bone
Journal:  Rheumatol Int       Date:  2010-12-14       Impact factor: 2.631

7.  Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?

Authors:  Linda Mary Davies; Emily Anne Fargher; Karen Tricker; Peter Dawes; David L Scott; Deborah Symmons
Journal:  Ann Rheum Dis       Date:  2006-11-23       Impact factor: 19.103

Review 8.  Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.

Authors:  Larry W Moreland
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 9.  Review of health economics modelling in rheumatoid arthritis.

Authors:  Paul Emery
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years.

Authors:  E Wagner; K Ammer; G Kolarz; I Krajnc; E Palkonyai; O Scherak; C Schödl; F Singer; P Temesvari; A Wottawa
Journal:  Rheumatol Int       Date:  2007-04-11       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.